The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Choosing between imaging modalities in multiple myeloma: advice for physicians
Jens Hillengass, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the importance of choosing the optimal imaging test in multiple myeloma, highlighting the roles of PET-CT and whole-body MRI. Dr Hillengass emphasizes the need for a practical decision framework that considers the availability of imaging modalities, and suggests that whole-body MRI with functional imaging techniques may be the first choice if available, with PET-CT as a good second option. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
